EGA
PDLI

Eagle Global Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Eagle Global Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-205,190
Closed -$435K – 421
2016
Q4 		$435K Buy
+205,190
New +$573K 0.01% 227

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Eagle Global Advisors's PDLI Position: Q1 2017 in Review

Eagle Global Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q1 2017, closing a stake of 205,190 shares — an estimated $435K sold.

Eagle Global Advisors first reported a position in PDLI in Q4 2016 and held it in 1 quarter. The position peaked at $435K in Q4 2016. 174 funds tracked by Wall St. Rank hold PDLI as of Q1 2017.

  • Eagle Global Advisors reported no remaining PDL BioPharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • Eagle Global Advisors sold 205,190 PDL BioPharma, Inc. shares in Q1 2017, an estimated $435K.
  • Eagle Global Advisors first reported a position in PDL BioPharma, Inc. in Q4 2016 and held it in 1 quarter.
  • Eagle Global Advisors's PDL BioPharma, Inc. position peaked at $435K in Q4 2016.
  • 174 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2017.

Based on Eagle Global Advisors's 13F filing for Q1 2017, filed 9 May 2017.